Turnstone Biologics Corp. reported developments for a biotechnology company historically focused on Selected tumor-infiltrating lymphocyte therapy for solid tumors. Company news covered TIDAL-01 clinical and preclinical data, presentations at Society for Immunotherapy of Cancer meetings, quarterly financial results, pipeline prioritization, cost-containment measures, workforce restructuring, and Nasdaq listing matters.
Turnstone later discontinued TIDAL-01 clinical studies and halted further program development while reviewing strategic alternatives. Subsequent corporate-status disclosures documented an acquisition-related transition, Nasdaq delisting, and termination of Exchange Act registration for its common stock.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Turnstone Biologics (TSBX)?
Turnstone Biologics (TSBX) last closed at $0.355.
What is the market cap of Turnstone Biologics (TSBX)?
The market cap of Turnstone Biologics (TSBX) is approximately $8.2M.